{'fraction_non_alphanumeric': 0.01990049751243781, 'fraction_numerical': 0.001658374792703151, 'mean_word_length': 5.942528735632184, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Targeting the Myddosome in Systemic Autoimmunity: Ready for Prime Time?

Innate immune responses play key roles in the initiation and perpetuation of a variety of systemic autoimmune diseases, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).(1) While effective biologics and small molecules targeting innate and adaptive immune responses in these diseases are currently available, there are still significant gaps in the development of therapies that can hamper innate immune dysregulation in certain subgroups of patients where this pathway may play crucial pathogenic roles.